Literature DB >> 9529985

The influence of white matter hyperintensities on the clinical features of Parkinson's disease.

Y H Sohn1, J S Kim.   

Abstract

This study was designed to investigate the influence of white matter hyperintensities (WMH) on clinical features of Parkinson's disease (PD) patients. The study subjects were 44 patients with PD who took a brain MRI. The severity of Parkinsonian symptoms was assessed in both 'on' and 'off' states, using the UPDRS-motor score. Thirteen patients (30%) showed WMH. The patients with WMH were significantly older than those without WMH (67 +/- 5.7 vs 60 +/- 6.4 years). In both 'off' and 'on' states, the gait scores were significantly higher in patients with WMH than in those without WMH (1.6 +/- 0.18 vs 1.1 +/- 0.12, P < 0.05), but other motor symptom (tremor, bradykinesia, rigidity) scores between the two patient groups were not statistically different. After taking a single dose of oral levodopa/benserazide (200mg/50mg), the patients with WMH showed significantly less improvement in bradykinesia score than those without WMH (25 +/- 4.1% vs 40 +/- 4.0%, P < 0.05), but the improvements in other symptoms were comparable between the two groups. These results suggest that WMH on MRI may influence Parkinsonian motor symptoms, particularly gait symptom and levodopa-responsiveness to bradykinesia symptom.

Entities:  

Mesh:

Year:  1998        PMID: 9529985     DOI: 10.3349/ymj.1998.39.1.50

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  15 in total

1.  Clinical markers for identifying cholinergic deficits in Parkinson's disease.

Authors:  Martijn L T M Müller; Nicolaas I Bohnen; Vikas Kotagal; Peter J H Scott; Robert A Koeppe; Kirk A Frey; Roger L Albin
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

Review 2.  The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature.

Authors:  Branislav Veselý; Angelo Antonini; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2015-10-19       Impact factor: 3.575

3.  Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Natalia Zarzhevsky; Robert A Koeppe; Christopher W Bogan; Michael R Kilbourn; Kirk A Frey; Roger L Albin
Journal:  Brain       Date:  2011-06-08       Impact factor: 13.501

Review 4.  White matter lesions in Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Nat Rev Neurol       Date:  2011-02-22       Impact factor: 42.937

5.  Microstructural white matter alterations in patients with drug induced parkinsonism.

Authors:  Yoonju Lee; Yong Ho Choi; Jae Jung Lee; Hye Sun Lee; Young H Sohn; Jong-Min Lee; Phil Hyu Lee
Journal:  Hum Brain Mapp       Date:  2017-09-12       Impact factor: 5.038

6.  Quantitative brain measurements in community-dwelling elderly persons with mild parkinsonian signs.

Authors:  Elan D Louis; Adam M Brickman; Charles DeCarli; Scott A Small; Karen Marder; Nicole Schupf; Truman R Brown
Journal:  Arch Neurol       Date:  2008-12

7.  Age-related white matter changes.

Authors:  Yun Yun Xiong; Vincent Mok
Journal:  J Aging Res       Date:  2011-08-23

Review 8.  Comparing Cerebral White Matter Lesion Burdens between Parkinson's Disease with and without Dementia.

Authors:  Sun-Ah Choi; Virgilio Gerald H Evidente; John N Caviness
Journal:  J Mov Disord       Date:  2010-04-30

9.  White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease.

Authors:  Jennifer Sartor; Kristina Bettecken; Felix P Bernhard; Marc Hofmann; Till Gladow; Tobias Lindig; Meltem Ciliz; Mara Ten Kate; Johanna Geritz; Sebastian Heinzel; Marije Benedictus; Philip Scheltens; Markus A Hobert; Walter Maetzler
Journal:  Front Aging Neurosci       Date:  2017-06-30       Impact factor: 5.750

10.  Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI.

Authors:  Thomas Jubault; Simona M Brambati; Clotilde Degroot; Benoît Kullmann; Antonio P Strafella; Anne-Louise Lafontaine; Sylvain Chouinard; Oury Monchi
Journal:  PLoS One       Date:  2009-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.